Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections

Zahoor Ahmad, Mostafa M. Fraig, Gregory P. Bisson, Eric Nuermberger, Jacques H. Grosset, Petros Karakousis

Research output: Contribution to journalArticle

Abstract

Recent in vitro pharmacokinetic data suggest that the currently recommended dose of pyrazinamide may be suboptimal for killing intracellular bacilli in humans. We evaluated a range of pyrazinamide doses against intracellular and extracellular Mycobacterium tuberculosis in chronically infected mice and guinea pigs, respectively. Antibiotics were given five times weekly for 4 weeks beginning 28 days after infection. Human-equivalent doses of isoniazid reduced lung bacterial counts 10-fold in each species. Pyrazinamide given at 1/4 and 1/2 the human-equivalent dose was minimally active, while human-equivalent doses reduced lung bacterial counts by ∼1.0 log10 in each species. Doubling the human-equivalent dose of pyrazinamide reduced the lung bacillary burden by 1.7 and 3.0 log10 in mice and guinea pigs, respectively. As in humans and mice, pyrazinamide showed significant synergy with rifampin in guinea pigs. Clinical studies are warranted to investigate the sterilizing activity and tolerability of higher doses of pyrazinamide in combination tuberculosis regimens.

Original languageEnglish (US)
Pages (from-to)1527-1532
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume55
Issue number4
DOIs
StatePublished - Apr 2011

Fingerprint

Pyrazinamide
Tuberculosis
Animal Models
Infection
Guinea Pigs
Bacterial Load
Lung
Isoniazid
Rifampin
Mycobacterium tuberculosis
Bacillus
Pharmacokinetics
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections. / Ahmad, Zahoor; Fraig, Mostafa M.; Bisson, Gregory P.; Nuermberger, Eric; Grosset, Jacques H.; Karakousis, Petros.

In: Antimicrobial Agents and Chemotherapy, Vol. 55, No. 4, 04.2011, p. 1527-1532.

Research output: Contribution to journalArticle

@article{ab6fa01323f34d7f90a0f450b2e7754c,
title = "Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections",
abstract = "Recent in vitro pharmacokinetic data suggest that the currently recommended dose of pyrazinamide may be suboptimal for killing intracellular bacilli in humans. We evaluated a range of pyrazinamide doses against intracellular and extracellular Mycobacterium tuberculosis in chronically infected mice and guinea pigs, respectively. Antibiotics were given five times weekly for 4 weeks beginning 28 days after infection. Human-equivalent doses of isoniazid reduced lung bacterial counts 10-fold in each species. Pyrazinamide given at 1/4 and 1/2 the human-equivalent dose was minimally active, while human-equivalent doses reduced lung bacterial counts by ∼1.0 log10 in each species. Doubling the human-equivalent dose of pyrazinamide reduced the lung bacillary burden by 1.7 and 3.0 log10 in mice and guinea pigs, respectively. As in humans and mice, pyrazinamide showed significant synergy with rifampin in guinea pigs. Clinical studies are warranted to investigate the sterilizing activity and tolerability of higher doses of pyrazinamide in combination tuberculosis regimens.",
author = "Zahoor Ahmad and Fraig, {Mostafa M.} and Bisson, {Gregory P.} and Eric Nuermberger and Grosset, {Jacques H.} and Petros Karakousis",
year = "2011",
month = "4",
doi = "10.1128/AAC.01524-10",
language = "English (US)",
volume = "55",
pages = "1527--1532",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "4",

}

TY - JOUR

T1 - Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections

AU - Ahmad, Zahoor

AU - Fraig, Mostafa M.

AU - Bisson, Gregory P.

AU - Nuermberger, Eric

AU - Grosset, Jacques H.

AU - Karakousis, Petros

PY - 2011/4

Y1 - 2011/4

N2 - Recent in vitro pharmacokinetic data suggest that the currently recommended dose of pyrazinamide may be suboptimal for killing intracellular bacilli in humans. We evaluated a range of pyrazinamide doses against intracellular and extracellular Mycobacterium tuberculosis in chronically infected mice and guinea pigs, respectively. Antibiotics were given five times weekly for 4 weeks beginning 28 days after infection. Human-equivalent doses of isoniazid reduced lung bacterial counts 10-fold in each species. Pyrazinamide given at 1/4 and 1/2 the human-equivalent dose was minimally active, while human-equivalent doses reduced lung bacterial counts by ∼1.0 log10 in each species. Doubling the human-equivalent dose of pyrazinamide reduced the lung bacillary burden by 1.7 and 3.0 log10 in mice and guinea pigs, respectively. As in humans and mice, pyrazinamide showed significant synergy with rifampin in guinea pigs. Clinical studies are warranted to investigate the sterilizing activity and tolerability of higher doses of pyrazinamide in combination tuberculosis regimens.

AB - Recent in vitro pharmacokinetic data suggest that the currently recommended dose of pyrazinamide may be suboptimal for killing intracellular bacilli in humans. We evaluated a range of pyrazinamide doses against intracellular and extracellular Mycobacterium tuberculosis in chronically infected mice and guinea pigs, respectively. Antibiotics were given five times weekly for 4 weeks beginning 28 days after infection. Human-equivalent doses of isoniazid reduced lung bacterial counts 10-fold in each species. Pyrazinamide given at 1/4 and 1/2 the human-equivalent dose was minimally active, while human-equivalent doses reduced lung bacterial counts by ∼1.0 log10 in each species. Doubling the human-equivalent dose of pyrazinamide reduced the lung bacillary burden by 1.7 and 3.0 log10 in mice and guinea pigs, respectively. As in humans and mice, pyrazinamide showed significant synergy with rifampin in guinea pigs. Clinical studies are warranted to investigate the sterilizing activity and tolerability of higher doses of pyrazinamide in combination tuberculosis regimens.

UR - http://www.scopus.com/inward/record.url?scp=79953193416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953193416&partnerID=8YFLogxK

U2 - 10.1128/AAC.01524-10

DO - 10.1128/AAC.01524-10

M3 - Article

C2 - 21282447

AN - SCOPUS:79953193416

VL - 55

SP - 1527

EP - 1532

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 4

ER -